Skip to main navigation Skip to search Skip to main content

Generation of Tolerogenic Dendritic Cells for Cell Therapy in Multiple Sclerosis.

Student thesis: Doctoral thesis

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system. Current treatments for relapsing-remitting multiple sclerosis (RR-MS) patients decrease the frequency of relapses and reduce inflammatory activity in a nonspecific manner, but their effect on disease progression is still unclear. Therefore, in order to modify the course of MS, new and more specific therapeutic approaches are necessary. Specific inhibition or deletion of autoreactive T cells represents an interesting goal for restoring peripheral tolerance in autoimmune diseases such as MS. _x000D_ The main goal of this work has been to generate and characterize tolerogenic dendritic cells (tolDCs) from RR-MS patients, loaded with myelin peptides as specific antigen, as a therapeutic tool to re-establish tolerance to myelin-antigens in these patients._x000D_ Our results show that using different immunosuppressive drugs and different maturation stimulus led to the generation of clinical-grade tolDCs products with differences that are relevant to therapeutic applicability. We evaluated the viability, phenotype, cytokine profile, stability and functionality of these tolDCs. The comparison of different pharmacological grade tolerogenic agents (dexamethasone, rapamycin and vitamin-D3) led to the observation that dexamethasone-treated DCs showed a semi-mature phenotype and high IL-10 secretion; that rapamycin-treated DCs impaired IFN-γ in co-cultured T cells and expanded T regulatory cells; and finally that vitamin-D3-treated DCs presented a semi-mature phenotype, produced IL-10, and reduced IFN-γ in T cells. These features, along with their reproducibility among different samples, made consider vitamin-D3 as the most convenient of the three compared agents to generate tolDCs for MS therapy. Regarding the maturation of tolDCs, the cytokine cocktail (composed by TNF-α, IL-1β and PGE-2) was determined as the optimal maturation stimulus to generate tolDCs (induced by vitamin-D3 treatment), since these tolDCs were the unique exhibiting functional stability and capability to suppress an immune response in vitro. _x000D_ The generation and characterization of tolDCs from RR-MS patients (generated with vitD3 and maturated with the pro-inflammatory cytokine cocktail), showed no significant differences compared with tolDCs generated from healthy controls, both presenting a tolerogenic profile. Importantly, myelin peptide-loaded tolDCs from RR-MS patients induced antigen-specific and stable hyporesponsiveness in autologous myelin-reactive T cells in vitro._x000D_ Altogether this work has conducted to the development of a protocol to generate clinical-grade tolDCs and set up the bases for their use as a therapeutic tool to re-establish tolerance in RR-MS patients.
Date of Award4 Jun 2012
Original languageEnglish
SupervisorEva Maria Cabeza Martinez Caceres (Director) & Francisco Enrique Borras Serres (Director)

Cite this

'